Mónica Povedano

Mónica Povedano

Head of department of neurophysiology and Coordinator of ALS unit

Mónica Povedano is an expert in neuromuscular disease and obtained her medical degree from the University of Barcelona. She is a specialist in Neurophysiology and currently coordinates the Motor Neuron Functional Unit of the Service of Neurology at the Bellvitge University Hospital, Institute of Biomedical Research of Bellvitge (IDIBELL). The Motor Neuron Functional Unit treats patients with ALS, SMA and other motor neuron diseases and is a referral centre for the local community and beyond. Her research interests are many, and include the study of subgroups of ALS, biomarker analysis, epidemiology, genetics but also to find treatments to improve swallowing and nutrition in ALS patients. Finally, she is also interested in interventions to prevent cognitive decline in patients with ALS. In 2017 she received an award for Professional Excellence from the Barcelona Medical College.

Connect
Connect trials
Recruiting
Phase iii

PHOENIX trial

Industry trial

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.

Read more
Recruiting
Phase iii

ADORE Trial

Industry trial

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).

Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.

Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.

Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more